Valued at $125.0M at its later-stage round, Feb 2025. Nothing has traded since.
- ·The complete investor list: 11 names
- ·Watch Vivace Therapeutics: the Monday email on marks, rounds and moves
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Vivace Therapeutics funding history
4 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Feb 2025 | Later Stage VC (Series D) | $35.0M | ▮ | ▮ |
| Dec 2020 | Early Stage VC | $30.0M | ▮ | ▮ |
| May 2017 | Early Stage VC | $8.0M | ▮ | ▮ |
| Jan 2015 | Early Stage VC | $5.0M | ▮ | ▮ |
Membership and data by Private Market View
Vivace Therapeutics valuation
Vivace Therapeutics was valued at $125 million at its later-stage round in Feb 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Vivace Therapeutics raised?
Vivace Therapeutics has raised $105 million across 4 recorded rounds since 2015. The largest was an $8 million early-stage round in May 2017; the most recent was a $35 million Series D in Feb 2025.
Vivace Therapeutics has filed 5 Form Ds with the SEC since 2015, most recently in Mar 2025 ($17.5 million sold to 5 investors).
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Imbria Pharmaceuticals ($132 million), Tahoe ($131 million) and Arsenal Medical ($124 million).
How Vivace Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Vivace Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →
Frequently asked about Vivace Therapeutics
- What is Vivace Therapeutics worth?
- Vivace Therapeutics is valued at $125.0M as of Oct 2026. Valued at $125.0M at its later-stage round, Feb 2025. Nothing has traded since.
- How much has Vivace Therapeutics raised?
- Vivace Therapeutics has raised $105.0M in total funding across 4 recorded rounds.
- When did Vivace Therapeutics last raise?
- Vivace Therapeutics last raised in Feb 2025 (Later Stage VC (Series D)), raising $35.0M.